HBV News and Research

RSS

Does HBV infection induce acute cellular DNA damage?

Eukaryotic cells employ multiple strategies of checkpoint signaling and DNA repair mechanisms to monitor and repair damaged DNA.

11 Nov 2008

FDA approves DNA test to measure hepatitis B viral load

The U.S. Food and Drug Administration today approved the first nucleic acid test for hepatitis B virus (HBV) that measures the amount of viral DNA (viral load) in a patient's blood. Assessing a patient's viral load provides health care professionals with a highly sensitive method for gauging the progress of antiviral therapy in patients with chronic HBV infections.

5 Sep 2008

Hunt for baby denied HBV shot

Authorities in New South Wales, Australia, continue to search for a couple who have refused to have their newborn baby immunised against hepatitis B.

25 Aug 2008

Viread approved for chronic hepatitis B

The FDA has approved Viread (tenofovir disoproxil fumarate) as a treatment option for adults with chronic hepatitis B, a serious liver disease.

11 Aug 2008

EpiCept and GNI partner to develop anti-viral hepatitis drug in Asia

GNI Ltd and EpiCept Corporation have announced that they have reached agreement to develop a new therapeutic drug, EP1013, in Asia, Australia, and New Zealand, for late-stage viral infection-induced hepatitis. EpiCept will retain the rights in the rest of the world. GNI’s wholly owned subsidiary, Shanghai Genomics, will start preparation for pre-IND and clinical development in China immediately.

17 Jul 2008

Hepatitis B virus triggers cell 'suicide' in patients with chronic infection

Scientists from UCL (University College London) have identified a key difference between people who can fight the Hepatitis B virus (HBV) off successfully and those who fail to do so - that a group of cells important in controlling the disease are triggered to 'commit suicide' in patients who are chronically infected.

9 Apr 2008

BARACLUDE data show low resistance over 5 years in nucleoside-naive hepatitis B patients

New BARACLUDE (entecavir) data presented demonstrated a continued low incidence of resistance in nucleoside-naïve patients through five years of treatment. In the nucleoside-naïve chronic hepatitis B patients analyzed, no additional patient developed resistance in the fifth year (n=108).

25 Mar 2008

Abbott receives approval for HUMIRA (Adalimumab) for polyarticular juvenile idiopathic arthritis

Abbott has announced that it has received U.S. Food and Drug Administration (FDA) approval to market HUMIRA (adalimumab) as a treatment to reduce signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients four years of age and older.

26 Feb 2008

New virus drug will have to shoot at moving targets

The reproduction of

22 Oct 2007

Low prevalence of Helicobacter pylori in HIV-positive patients

Helicobacter pylori has been extensively studied and proven to be the main cause of chronic gastritis and peptic ulcer in the HIV-negative population.

17 Oct 2007

FDA fast tracks PI-88 for the treatment of post resection liver cancer

Progen Pharmaceuticals Limited has announced that its investigational anti-cancer drug PI-88 has been awarded Fast Track status by the U.S. Food and Drug Administration (FDA).

25 Sep 2007

Liver cancer marker could yield blood test for early detection

In the face of an emerging liver cancer crisis in Asia, researchers at the Chinese University of Hong Kong have developed a test that could help millions.

18 Sep 2007

Research looks at hepatitis C recovery

More than 3% of world population is infected with hepatitis C virus (HCV). The outcome of HCV infections is either self recovery or chronic hepatitis, and many of the chronic infections will develop into liver cirrhosis or liver cancer.

30 Aug 2007

Protecting HIV patients from Hep B

Since the transmission of HIV and Hepatitis B virus (HBV) are so similar, individuals infected with one of these viruses are at a significantly increased risk for contracting the other.

19 Jul 2007

Many needle-stick injuries unreported

A survey of nearly 700 surgical residents in 17 U.S. medical centers finds that more than half failed to report needle-stick injuries involving patients whose blood could be a source of HIV, hepatitis and other infections.

28 Jun 2007

When HIV and liver disease co-exist

Since successful antiretroviral therapies have made HIV a treatable condition, more HIV patients who are also infected with hepatitis B or C are experiencing the progression of their liver disease.

3 Jun 2007

Liver cancer patients with high serum levels of hepatitis B virus face poorer outcomes

In the June issue of Hepatology, a journal published by John Wiley & Sons on behalf of the American Association for the Study of Liver Diseases (AASLD), researchers report their findings from the first-ever study examining the prognostic value of serum HBV DNA levels for patients with liver cancer undergoing chemotherapy.

3 Jun 2007

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott has announced it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. and juvenile idiopathic arthritis (JIA) in the European Union (EU).

9 May 2007

Bristol-Myers Squibb announces new results of Baraclude (entecavir) resistance monitoring program

Bristol-Myers Squibb Company has announced new results of the Baraclude (entecavir) resistance monitoring program, which found a continued low incidence of resistance in studies of nucleoside-naive chronic hepatitis B patients through four years of treatment.

16 Apr 2007

CuraGen announces results with Belinostat and Velafermin

CuraGen Corporation has announced that new preclinical data on belinostat (PXD101), a histone deacetylase (HDAC) inhibitor being investigated for the treatment of cancer, and velafermin, a protein being investigated for the prevention of severe oral mucositis, will be presented at the upcoming American Association for Cancer Research (AACR) 2007 Annual Meeting in Los Angeles, CA, April 14-18, 2007.

15 Apr 2007